Condition: Acute Lymphoblastic Leukemia · Acute Lymphoblastic Leukemia Recurrent · Acute Lymphoblastic Leukemia Refractory · Sponsor: King Hussein Cancer Center
Single-arm, prospective, open-label feasibility study evaluating the technical and operational feasibility of manufacturing autologous CD19-directed CAR-T cells (MB-CART19.1) at the point of care for the treatment of relapsed or refractory B-ALL in pediatric and adult patients.
This description comes directly from the study's public registry record.
Dr. Zaid Abdel Rahman, Consultant,Hematology/Oncology · +962797101838 · ZA.11040@KHCC.JO
Dr. Hasan Hashem, Consultant,Hematology/Oncology · 00962797207439 · hh.08847@khcc.jo
Always discuss trial participation with your own doctor first.
| King Hussein Cancer Center | Amman, Jordan | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07371403